Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02

AUTHORS

Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt

ABSTRACT

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects. METHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (≥ 65 years) treated with secukinumab 300 mg were compared with 841 younger subjects (18-64 years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed. RESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52 weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects. CONCLUSIONS: Secukinumab at the recommended dose (300 mg) is effective and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population. More... »

PAGES

135-144

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z

DOI

http://dx.doi.org/10.1007/s40266-018-0520-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100822287

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29404966


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chronic Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-17", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psoriasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Essen University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.410718.b", 
          "name": [
            "Department of Dermatology, University Hospital Essen (A\u00f6R), Hufelandstra\u00dfe 55, 45147, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00f6rber", 
        "givenName": "Andreas", 
        "id": "sg:person.01145551610.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145551610.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papavassilis", 
        "givenName": "Charis", 
        "id": "sg:person.0716272754.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716272754.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd., Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhosekar", 
        "givenName": "Vaishali", 
        "id": "sg:person.013137310337.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, Nuremberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reinhardt", 
        "givenName": "Maximilian", 
        "id": "sg:person.011331407423.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011331407423.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/jdv.12850", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000838975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2015.05.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003378700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40266-014-0156-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004634174", 
          "https://doi.org/10.1007/s40266-014-0156-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.det.2014.09.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004745752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2230.1994.tb01167.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006462973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000345623", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009856056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.109.192644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011029623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-013-0025-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012014989", 
          "https://doi.org/10.1007/s40259-013-0025-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2015.04.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012031820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.13814", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012326879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200623030-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018677119", 
          "https://doi.org/10.2165/00002512-200623030-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.08.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025225587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3001107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026879172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3001107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026879172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/09546634.2013.865009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028559094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.14115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030513281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035341201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035498917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2004.033217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035667423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.12110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041637344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archdermatol.2010.186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041812544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1314258", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049860938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1346-8138.12653", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052373019"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis.\nAIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects.\nMETHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (\u2265\u00a065\u00a0years) treated with secukinumab 300\u00a0mg were compared with 841 younger subjects (18-64\u00a0years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed.\nRESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52\u00a0weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects.\nCONCLUSIONS: Secukinumab at the recommended dose (300\u00a0mg) is effective and acceptably safe in subjects aged \u2265\u00a065\u00a0years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40266-018-0520-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1100990", 
        "issn": [
          "1170-229X", 
          "1179-1969"
        ], 
        "name": "Drugs & Aging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies", 
    "pagination": "135-144", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8adde5f4c1dd468f8da01a1e657c0c1f964649c3bf1b01d8b84f06018e2da4db"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29404966"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9102074"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40266-018-0520-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100822287"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40266-018-0520-z", 
      "https://app.dimensions.ai/details/publication/pub.1100822287"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000493.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s40266-018-0520-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      65 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40266-018-0520-z schema:about N009f0e36d44143dd99e45ac575e5d447
2 N04dcaf3fdf2f4e4d9ea305bad4cd433e
3 N213e547dc74c48eb8dc25792e12271c2
4 N33691d4b00d647acab1962aabe3b7fbd
5 N3460aeecc93549f5a1e7ec13981b9d88
6 N44530f7c0cbf493fa2824f5e751ae462
7 N487531e214014c95914c8ec5c9c4f124
8 N5cbb67d07f39436c8a8758bd38a89394
9 N763c61b67cc540f5bedcf0c8b1c2f090
10 N83fb1f41e7104cc7a6e2e7ff3716b3fa
11 N84127d5b3ba6405e98b04ef8b7740e68
12 N8eef2f9d6b4042c59d8743bfcaf73042
13 N92897603204249e7a287ad6eabe4a368
14 N992739a795db4cf08d172ca9ce963562
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Naf61443c96d94bd6a96e927d93ae4ba5
18 schema:citation sg:pub.10.1007/s40259-013-0025-6
19 sg:pub.10.1007/s40266-014-0156-6
20 sg:pub.10.2165/00002512-200623030-00003
21 https://doi.org/10.1001/archdermatol.2010.186
22 https://doi.org/10.1016/j.det.2014.09.004
23 https://doi.org/10.1016/j.jaad.2015.04.011
24 https://doi.org/10.1016/j.jaad.2015.05.013
25 https://doi.org/10.1016/j.jaad.2016.08.008
26 https://doi.org/10.1056/nejmoa1314258
27 https://doi.org/10.1056/nejmoa1412679
28 https://doi.org/10.1111/1346-8138.12653
29 https://doi.org/10.1111/bjd.12110
30 https://doi.org/10.1111/bjd.13814
31 https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
32 https://doi.org/10.1111/jdv.12850
33 https://doi.org/10.1111/jdv.13354
34 https://doi.org/10.1111/jdv.14115
35 https://doi.org/10.1126/scitranslmed.3001107
36 https://doi.org/10.1136/ard.2004.033217
37 https://doi.org/10.1159/000345623
38 https://doi.org/10.1161/circulationaha.109.192644
39 https://doi.org/10.3109/09546634.2013.865009
40 schema:datePublished 2018-02
41 schema:datePublishedReg 2018-02-01
42 schema:description BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects. METHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (≥ 65 years) treated with secukinumab 300 mg were compared with 841 younger subjects (18-64 years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed. RESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52 weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects. CONCLUSIONS: Secukinumab at the recommended dose (300 mg) is effective and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf N920031dbf6f94ec0b3ba28d243f7ff13
47 Nf570cf29c1de4da98b97644c8183f40d
48 sg:journal.1100990
49 schema:name Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
50 schema:pagination 135-144
51 schema:productId N5f34e0ca68234f67b3747fe9b5d2ac8d
52 N7cca7d6d1a9b45a291354216a7acf57f
53 Nbee29c60305845fdba79658eb086f05e
54 Ne0e15b65f4764bc09982a40767aa0ec0
55 Nf93e6eafae80473bb84155025aed72fe
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100822287
57 https://doi.org/10.1007/s40266-018-0520-z
58 schema:sdDatePublished 2019-04-11T00:12
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N68851a26f3444107bef112231fbe16bf
61 schema:url http://link.springer.com/10.1007/s40266-018-0520-z
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N009f0e36d44143dd99e45ac575e5d447 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Aged
67 rdf:type schema:DefinedTerm
68 N03bd4cf6003f49c1b7ab8c360a8bd51f rdf:first sg:person.011331407423.03
69 rdf:rest rdf:nil
70 N04dcaf3fdf2f4e4d9ea305bad4cd433e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Psoriasis
72 rdf:type schema:DefinedTerm
73 N213e547dc74c48eb8dc25792e12271c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Severity of Illness Index
75 rdf:type schema:DefinedTerm
76 N33691d4b00d647acab1962aabe3b7fbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Female
78 rdf:type schema:DefinedTerm
79 N3460aeecc93549f5a1e7ec13981b9d88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Interleukin-17
81 rdf:type schema:DefinedTerm
82 N44530f7c0cbf493fa2824f5e751ae462 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Chronic Disease
84 rdf:type schema:DefinedTerm
85 N487531e214014c95914c8ec5c9c4f124 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Middle Aged
87 rdf:type schema:DefinedTerm
88 N535267e34cad441fb168dc33816ed694 rdf:first sg:person.0716272754.57
89 rdf:rest N6eeeca55a07f4d8097844a86dd9f3510
90 N5cbb67d07f39436c8a8758bd38a89394 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Multicenter Studies as Topic
92 rdf:type schema:DefinedTerm
93 N5f34e0ca68234f67b3747fe9b5d2ac8d schema:name pubmed_id
94 schema:value 29404966
95 rdf:type schema:PropertyValue
96 N68851a26f3444107bef112231fbe16bf schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N6eeeca55a07f4d8097844a86dd9f3510 rdf:first sg:person.013137310337.01
99 rdf:rest N03bd4cf6003f49c1b7ab8c360a8bd51f
100 N763c61b67cc540f5bedcf0c8b1c2f090 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Clinical Trials, Phase III as Topic
102 rdf:type schema:DefinedTerm
103 N7cca7d6d1a9b45a291354216a7acf57f schema:name readcube_id
104 schema:value 8adde5f4c1dd468f8da01a1e657c0c1f964649c3bf1b01d8b84f06018e2da4db
105 rdf:type schema:PropertyValue
106 N83fb1f41e7104cc7a6e2e7ff3716b3fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Humans
108 rdf:type schema:DefinedTerm
109 N84127d5b3ba6405e98b04ef8b7740e68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Treatment Outcome
111 rdf:type schema:DefinedTerm
112 N8eef2f9d6b4042c59d8743bfcaf73042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Male
114 rdf:type schema:DefinedTerm
115 N920031dbf6f94ec0b3ba28d243f7ff13 schema:issueNumber 2
116 rdf:type schema:PublicationIssue
117 N92897603204249e7a287ad6eabe4a368 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antibodies, Monoclonal
119 rdf:type schema:DefinedTerm
120 N992739a795db4cf08d172ca9ce963562 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Randomized Controlled Trials as Topic
122 rdf:type schema:DefinedTerm
123 Naf61443c96d94bd6a96e927d93ae4ba5 rdf:first sg:person.01145551610.69
124 rdf:rest N535267e34cad441fb168dc33816ed694
125 Nbee29c60305845fdba79658eb086f05e schema:name nlm_unique_id
126 schema:value 9102074
127 rdf:type schema:PropertyValue
128 Ne0e15b65f4764bc09982a40767aa0ec0 schema:name dimensions_id
129 schema:value pub.1100822287
130 rdf:type schema:PropertyValue
131 Nf570cf29c1de4da98b97644c8183f40d schema:volumeNumber 35
132 rdf:type schema:PublicationVolume
133 Nf93e6eafae80473bb84155025aed72fe schema:name doi
134 schema:value 10.1007/s40266-018-0520-z
135 rdf:type schema:PropertyValue
136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
137 schema:name Medical and Health Sciences
138 rdf:type schema:DefinedTerm
139 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
140 schema:name Clinical Sciences
141 rdf:type schema:DefinedTerm
142 sg:journal.1100990 schema:issn 1170-229X
143 1179-1969
144 schema:name Drugs & Aging
145 rdf:type schema:Periodical
146 sg:person.011331407423.03 schema:affiliation https://www.grid.ac/institutes/grid.467675.1
147 schema:familyName Reinhardt
148 schema:givenName Maximilian
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011331407423.03
150 rdf:type schema:Person
151 sg:person.01145551610.69 schema:affiliation https://www.grid.ac/institutes/grid.410718.b
152 schema:familyName Körber
153 schema:givenName Andreas
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145551610.69
155 rdf:type schema:Person
156 sg:person.013137310337.01 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
157 schema:familyName Bhosekar
158 schema:givenName Vaishali
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01
160 rdf:type schema:Person
161 sg:person.0716272754.57 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
162 schema:familyName Papavassilis
163 schema:givenName Charis
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716272754.57
165 rdf:type schema:Person
166 sg:pub.10.1007/s40259-013-0025-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012014989
167 https://doi.org/10.1007/s40259-013-0025-6
168 rdf:type schema:CreativeWork
169 sg:pub.10.1007/s40266-014-0156-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004634174
170 https://doi.org/10.1007/s40266-014-0156-6
171 rdf:type schema:CreativeWork
172 sg:pub.10.2165/00002512-200623030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018677119
173 https://doi.org/10.2165/00002512-200623030-00003
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1001/archdermatol.2010.186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041812544
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.det.2014.09.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004745752
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.jaad.2015.04.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012031820
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.jaad.2015.05.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003378700
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.jaad.2016.08.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025225587
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1056/nejmoa1314258 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049860938
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1056/nejmoa1412679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035341201
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1111/1346-8138.12653 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052373019
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1111/bjd.12110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041637344
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1111/bjd.13814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012326879
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1111/j.1365-2230.1994.tb01167.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006462973
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1111/jdv.12850 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000838975
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1111/jdv.13354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035498917
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1111/jdv.14115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030513281
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1126/scitranslmed.3001107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026879172
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1136/ard.2004.033217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035667423
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1159/000345623 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009856056
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1161/circulationaha.109.192644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011029623
210 rdf:type schema:CreativeWork
211 https://doi.org/10.3109/09546634.2013.865009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028559094
212 rdf:type schema:CreativeWork
213 https://www.grid.ac/institutes/grid.410718.b schema:alternateName Essen University Hospital
214 schema:name Department of Dermatology, University Hospital Essen (AöR), Hufelandstraße 55, 45147, Essen, Germany
215 rdf:type schema:Organization
216 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
217 schema:name Novartis Pharma AG, Basel, Switzerland
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
220 schema:name Novartis Healthcare Pvt. Ltd., Hyderabad, India
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.467675.1 schema:alternateName Novartis (Germany)
223 schema:name Novartis Pharma GmbH, Nuremberg, Germany
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...